Prospective Double-Blind Study of Zidovudine (AZT) in Early Stage HIV infection
Abstract
High cost and toxicity of the anti-viral drug 3'-Azido-thymidine (Zidovudine) makes necessary a careful study of its possible benefits. Chronic low-level dosing of a population with signs and symptoms of early stage HIV infection may sufficiently inhibit viral replication to alter the rate of disease progression, with acceptable toxicity. Data provided by the present study will help answer these cost/benefit questions. This study will also provide valuable experience in application of state of the art HIV culture and antigen detection methods as well as CD4 cell counts, Toxoplasma and Cytomegalovirus antibody tests, to an investigation of clinical AIDS. This study is a valuable adjunct to clinical care, providing necessary improvements to clinical standards for compulsory follow-up asymptomatic HIV infected patients at FAMC.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 1988
- Accession Number
- ADA197390
Entities
People
- Shannon M. Harrison